Generic Drug Tariffs Are Not Yet Policy. Companies Still Need a Plan
President Trump has announced that imported generic drugs would remain subject to a zero tariff for two years beginning August 1, 2026. The tariff would then rise to 100% for one year and 200% thereafter. The stated objective is to encourage more pharmaceutical manufacturing in the United States.
The announcement has generated immediate concern about drug prices, shortages, and the exposure of manufacturers that rely heavily on production outside the United States.
There is an important distinction, however, between a policy announcement and an enforceable tariff.
As of July 23, 2026, no new executive order, presidential proclamation, Federal Register notice, Customs and Border Protection guidance, or amendment to the Harmonized Tariff Schedule has been issued to implement the announced generic-drug tariffs.
The existing legal position still says the opposite. The pharmaceutical tariff proclamation issued in April expressly provides that generic pharmaceuticals, biosimilars, and their associated ingredients are not subject to Section 232 tariffs “at this time.” It directs the Secretary of Commerce to continue monitoring generic imports and report within one year on whether additional action may be appropriate.
The announced tariff schedule should therefore be treated as a serious business signal, not as an operative legal obligation.
The Details Will Determine the Real Exposure
Any implementing action would need to answer questions that could materially change its commercial effect.
Would the tariffs apply only to finished generic drugs, or also to active pharmaceutical ingredients and key starting materials? Would biosimilars remain within the generic category? How would the government determine a product’s country of origin when different manufacturing stages occur in different jurisdictions?
It is also unclear whether manufacturers could qualify for lower rates by building or expanding U.S. production. The existing branded-pharmaceutical tariff framework provides different treatment for certain companies with approved onshoring plans, pricing agreements, or operations in countries covered by trade arrangements. Companies should not assume that the same structure will automatically be extended to generics.
Until those details are established, manufacturers cannot calculate their potential tariff liability. Distributors, pharmacies, health plans, and healthcare providers also cannot determine how additional costs might move through the supply chain.
Generic-Drug Economics Make the Risk Different
Generic drugs frequently operate under narrow margins, competitive purchasing contracts, and reimbursement structures that may not adjust quickly when acquisition costs rise.
A manufacturer may not be able to absorb a substantial tariff. It may also lack the contractual ability to pass the full cost to a wholesaler or customer.
For some products, the response may not simply be a higher price. Manufacturers could reconsider whether it remains economically viable to continue supplying a particular drug to the U.S. market.
That creates a potential availability risk, especially for low-margin products, drugs with few suppliers, and medicines already vulnerable to shortage.
Reshoring could strengthen pharmaceutical supply chains over time. Tariffs alone, however, do not resolve the capital, workforce, regulatory, contracting, reimbursement, and purchasing challenges that determine whether domestic generic manufacturing is commercially sustainable.
What Companies Should Do Now
Companies should not treat the announced rates as settled policy or make definitive customs conclusions before formal implementation documents are issued. They should, however, begin evaluating their potential exposure now.
Generic manufacturers and importers can begin mapping products by manufacturing location, ingredient source, country of origin, margin, tariff classification, and contractual ability to pass through higher costs.
Distributors, pharmacies, health plans, and health systems should identify products for which a tariff could create the greatest cost or availability risk.
Investors should evaluate which companies possess credible domestic manufacturing options and which remain dependent on policy exemptions or continued access to lower-cost foreign production.
Leaders should also model several possible outcomes, including:
Continued exemption for generic drugs
Tariffs limited to selected products, ingredients, or countries
Reduced rates for companies making approved U.S. manufacturing commitments
Broader tariffs covering both finished products and pharmaceutical ingredients
Each scenario could produce different decisions involving sourcing, inventory, contracts, capital investment, pricing, and continued participation in the U.S. market.
The tariff is not yet policy. The strategic question is whether companies will understand their exposure before it becomes one.
Lanton Strategies International advises healthcare, life-sciences, and investment organizations on how trade policy, regulation, reimbursement, market access, and capital developments affect business strategy and commercial execution across the United States, European Union, and United Kingdom.